Lung cancer: diagnosis and management

Treatment pathways

Interactive PDF of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer (PDF 1.23 MB)

Squamous pathway: No targetable mutations, PD-L1 less than 50% (PDF 79 KB)

Squamous pathway: No targetable mutations, PD-L1 50% or higher (PDF 121 KB)

Squamous pathway: RET fusion positive, PD-L1 less than 50% (PDF 90 KB)

Squamous pathway: RET fusion positive, PD-L1 50% or higher (PDF 128 KB)

Squamous pathway: KRAS G12C positive, PD-L1 less than 50% (PDF 87 KB)

Squamous pathway: KRAS G12C positive, PD-L1 50% or higher (PDF 125 KB)

Squamous pathway: METex14 skipping alteration, PD-L1 less than 50%  (PDF 90 KB)

Squamous pathway: METex14 skipping alteration, PD-L1 50% or higher (PDF 128 KB)

Squamous pathway: BRAF V600 positive, PD-L1 less than 50% (PDF 83 KB)

Squamous pathway: BRAF V600 positive, PD-L1 50% or higher (PDF 125 KB)

Non-squamous pathway: No targetable mutations, PD-L1 less than 50% (PDF 82 KB)

Non-squamous pathway: No targetable mutations, PD-L1 50% or higher (PDF 100 KB)

Non-squamous pathway: RET fusion positive, PD-L1 less than 50% (PDF 94 KB)

Non-squamous pathway: RET fusion positive, PD-L1 50% or higher (PDF 110 KB)

Non-squamous pathway: KRAS G12C positive, PD-L1 less than 50% (PDF 88 KB)

Non-squamous pathway: KRAS G12C positive, PD-L1 50% or higher (PDF 104 KB)

Non-squamous pathway: METex14 skipping alteration, PD-L1 less than 50% (PDF 94 KB)

Non-squamous pathway: METex14 skipping alteration, PD-L1 50% or higher (PDF 110 KB)

Non-squamous pathway: BRAF V600 positive, PD-L1 less than 50% (PDF 88 KB)

Non-squamous pathway: BRAF V600 positive, PD-L1 50% or higher (PDF 106 KB)

Non-squamous pathway: ROS-1 positive (PDF 82 KB)

Non-squamous pathway: EGFR-TK positive (PDF 106 KB)

Non-squamous pathway: ALK positive (PDF 87 KB)

Fully accessible Word version of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer (Word 61 KB)

Squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% (Word 32 KB)

Squamous fully accessible summary: No targetable mutations, PD-L1 50% or higher (Word 32 KB)

Squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% (Word 34 KB)

Squamous fully accessible summary: RET fusion positive, PD-L1 50% or higher (Word 33 KB)

Squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% (Word 33 KB)

Squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or higher (Word 32 KB)

Squamous fully accessible summary: METex14 skipping alteration, PD-L1 less than 50%  (Word 34 KB)

Squamous fully accessible summary: METex14 skipping alteration, PD-L1 50% or higher (Word 33 KB)

Squamous fully accessible summary: BRAF V600 positive, PD-L1 less than 50% (Word 33 KB)

Squamous fully accessible summary: BRAF V600 positive, PD-L1 50% or higher (Word 32 KB)

Non-squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% (Word 32 KB)

Non-squamous fully accessible summary: No targetable mutations, PD-L1 50% or higher (Word 32 KB)

Non-squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% (Word 35 KB)

Non-squamous fully accessible summary: RET fusion positive, PD-L1 50% or higher (Word 34 KB)

Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% (Word 33 KB)

Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or higher (Word 33 KB)

Non-squamous fully accessible summary: METex14 skipping alteration, PD-L1 less than 50% (Word 35 KB)

Non-squamous fully accessible summary: METex14 skipping alteration, PD-L1 50% or higher (Word 34 KB)

Non-squamous fully accessible summary: BRAF V600 positive, PD-L1 less than 50% (Word 34 KB)

Non-squamous fully accessible summary: BRAF V600 positive, PD-L1 50% or higher (Word 33 KB)

Non-squamous fully accessible summary: ROS-1 positive (Word 33 KB)

Non-squamous fully accessible summary: EGFR-TK positive (Word 33 KB)

Non-squamous fully accessible summary: ALK positive (Word 34 KB)

Endorsed resource – PET-CT reporting training programme (lymphoma, head and neck cancer, lung cancer, oesophageal cancer modules)

About the Into practice guide